top1p1: A Potential Drug Target and Biomarker for DNA Topoisomerase I Pseudogene 1

Target Name: TOP1P1

NCBI ID: G7151

TOP1P1

Other Name(s): DNA topoisomerase I pseudogene 1

top1p1: A Potential Drug Target and Biomarker for DNA Topoisomerase I Pseudogene 1

DNA topoisomerase I (DNA top I) is a crucial enzyme in the replication process of DNA in eukaryotic cells. It plays a vital role in maintaining the integrity of DNA replication by ensuring the orderly and accurate transfer of genetic information from the mother to the offspring. The pseudogene 1 (TOP1P1) is a non-coding DNA sequence located on chromosome 22q11. Although it has no functional role in the replication process, it is expressed in the same region of the DNA as other DNA top I pseudogenes, including top1p2 and top1p3.

Recent studies have identified top1p1 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. This is due to its unique expression pattern and the potential it may hold for targeting diseases that are characterized by disruptions in DNA replication.

Potential Drug Target

The potential drug target for top1p1 is related to its unique expression pattern and its role in the replication process. It has been observed that top1p1 is highly expressed in various tissues, including brain, spleen, and pancreas, and is primarily expressed in the germinal center. This suggests that it may be a potential drug target for diseases that affect the germinal center, such as cancer, neurodegenerative diseases, and autoimmune disorders.

In addition, top1p1 has been shown to play a role in the regulation of cellular processes that are important for cancer progression, such as cell division, angiogenesis, and inflammation. It has been shown to contribute to the development and progression of various types of cancer, including neuroblastoma, a type of cancer that affects the nervous system.

Biomarker

The expression of top1p1 is a potential biomarker for diseases that are characterized by disruptions in DNA replication. This is because top1p1 is a key enzyme in the replication process and its dysfunction can lead to defects in DNA replication, which can be detected by various biomarkers.

For example, one potential biomarker for top1p1 dysfunction is the expression of anemia-related genes, such as HBA1 and HBA2. These genes are responsible for producing the erythropoietin (EPO) hormone, which is essential for the production of red blood cells. HBA1 and HBA2 are encoded by the top1p1 gene and are highly expressed in tissues that are affected by anemia, such as the liver, spleen, and kidneys.

Another potential biomarker for top1p1 dysfunction is the expression of genes involved in cell adhesion and migration. Top1p1 has been shown to play a role in the regulation of cell-cell adhesion and has been implicated in the development of various types of cancer. For example, the expression of the gene E-cadherin, which is involved in cell-cell adhesion, is highly correlated with the expression of top1p1 in various tissues.

Conclusion

In conclusion, top1p1 is a potential drug target and biomarker for various diseases due to its unique expression pattern and its role in the replication process. Its dysfunction has been implicated in the development and progression of cancer, as well as the regulation of cellular processes that are important for disease progression. Further research is needed to fully understand the potential of top1p1 as a drug target and biomarker for various diseases.

Protein Name: DNA Topoisomerase I Pseudogene 1

The "TOP1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TOP1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets